jetcityimage/iStock Editorial by way of Getty Photographs Eli Lilly (NYSE:LLY) shares rose ~7% premarket Tuesday after the corporate elevated its full-year outlook above consensus, citing a robust efficiency in its weight reduction merchandise in Q1 2024. Whereas LLY’s quarterly earnings exceeded estimates, the corporate underperformed in income as gross sales from its diabetes remedy Trulicity...
Latest in Fitness
Health Tips
Trending Lifestyle
Contact Information
- Do not hesitate to contact us if you have questions about the subscription or your ads publish. We are here to help!
- E-mail at [email protected]
- Give us a call at our toll-free number: ((888) 503-2390